BACKGROUND: Both the United States and Canada offer government-financed health insurance for the elderly, but few studies have compared care at the end of life for cancer patients between the two systems. METHODS: We identified care for non-small cell lung cancer (NSCLC) patients who died of cancer at age 65 years and older during 1999-2003. Patients were identified from US Surveillance, Epidemiology, and End Results (SEER)-Medicare data (N = 13,533) and the Ontario Cancer Registry (N = 8100). Health claims during the last 5 months of life identified chemotherapy and emergency room use, hospitalizations, and supportive care. We estimated rates per person-months (PM) for short-term survivors (died <6 months after diagnosis) and longer-term survivors (died ≥6 months after diagnosis), adjusting for demographic differences. To test whether monthly rates in Ontario were statistically significantly different from the United States, standardized differences were computed, and a 99% confidence interval (CI) was constructed to account for the multiple tests performed. All statistical tests were two-sided. RESULTS: Rates of chemotherapy use were statistically significantly higher for SEER-Medicare patients than Ontario patients in every month before death (short-term survivors at 5 months before death: SEER-Medicare, 33.2 patients per 100 PM vs Ontario, 9.5 per 100 PM, rate difference = 23.7 per 100 PM, 99% CI = 18.3 to 29.1 per 100 PM, P < .001; longer-term survivors at 5 months before death: SEER-Medicare, 24.4 patients per 100 PM vs Ontario, 14.5 per 100 PM, rate difference = 9.9 per 100 PM, 99% CI = 7.7 to 12.1 per 100 PM, P <. 001). During the last 30 days of life, fewer SEER-Medicare than Ontario patients were hospitalized (short-term survivors, 49.9 vs 78.6 patients per 100 PM, rate difference = 28.6 per 100 PM, 95% CI = 22.9 to 34.4 per 100 PM, P <. 001; longer-term survivors, 44.1 vs 67.1 patients per 100 PM, rate difference = 23.0 per 100 PM, 95% CI = 18.5 to 27.5 per 100 PM, P < .001). CONCLUSIONS: NSCLC patients in both Ontario and the United States used extensive end-of-life care. Limited availability of hospice care in Ontario and differing attitudes between the United States and Ontario regarding end-of-life care may explain the differences in practice patterns.
BACKGROUND: Both the United States and Canada offer government-financed health insurance for the elderly, but few studies have compared care at the end of life for cancerpatients between the two systems. METHODS: We identified care for non-small cell lung cancer (NSCLC) patients who died of cancer at age 65 years and older during 1999-2003. Patients were identified from US Surveillance, Epidemiology, and End Results (SEER)-Medicare data (N = 13,533) and the Ontario Cancer Registry (N = 8100). Health claims during the last 5 months of life identified chemotherapy and emergency room use, hospitalizations, and supportive care. We estimated rates per person-months (PM) for short-term survivors (died <6 months after diagnosis) and longer-term survivors (died ≥6 months after diagnosis), adjusting for demographic differences. To test whether monthly rates in Ontario were statistically significantly different from the United States, standardized differences were computed, and a 99% confidence interval (CI) was constructed to account for the multiple tests performed. All statistical tests were two-sided. RESULTS: Rates of chemotherapy use were statistically significantly higher for SEER-Medicare patients than Ontario patients in every month before death (short-term survivors at 5 months before death: SEER-Medicare, 33.2 patients per 100 PM vs Ontario, 9.5 per 100 PM, rate difference = 23.7 per 100 PM, 99% CI = 18.3 to 29.1 per 100 PM, P < .001; longer-term survivors at 5 months before death: SEER-Medicare, 24.4 patients per 100 PM vs Ontario, 14.5 per 100 PM, rate difference = 9.9 per 100 PM, 99% CI = 7.7 to 12.1 per 100 PM, P <. 001). During the last 30 days of life, fewer SEER-Medicare than Ontario patients were hospitalized (short-term survivors, 49.9 vs 78.6 patients per 100 PM, rate difference = 28.6 per 100 PM, 95% CI = 22.9 to 34.4 per 100 PM, P <. 001; longer-term survivors, 44.1 vs 67.1 patients per 100 PM, rate difference = 23.0 per 100 PM, 95% CI = 18.5 to 27.5 per 100 PM, P < .001). CONCLUSIONS:NSCLCpatients in both Ontario and the United States used extensive end-of-life care. Limited availability of hospice care in Ontario and differing attitudes between the United States and Ontario regarding end-of-life care may explain the differences in practice patterns.
Authors: Patti A Groome; Brian O'Sullivan; Jonathan C Irish; Deanna M Rothwell; Karleen Schulze; Padraig R Warde; Ken M Schneider; Robert G Mackenzie; D Ian Hodson; J Alex Hammond; Sunil P P Gulavita; Libni J Eapen; Peter F Dixon; Randy J Bissett; William J Mackillop Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544
Authors: P A Groome; B O'Sullivan; J C Irish; D M Rothwell; K S Math; R J Bissett; P R Dixon; L J Eapen; S P Gulavita; J A Hammond; D I Hodson; R G Mackenzie; K M Schneider; P R Warde; W J Mackillop Journal: J Clin Epidemiol Date: 2001-03 Impact factor: 6.437
Authors: S LoCoco; A Covens; M Carney; E Franssen; R Dogde; B Rosen; R Osborne; I Kerr; R Buckman; J Soper Journal: Gynecol Oncol Date: 1995-11 Impact factor: 5.482
Authors: Alexie Cintron; Mary B Hamel; Roger B Davis; Risa B Burns; Russell S Phillips; Ellen P McCarthy Journal: J Palliat Med Date: 2003-10 Impact factor: 2.947
Authors: L Barbera; H Seow; R Sutradhar; A Chu; F Burge; K Fassbender; K McGrail; B Lawson; Y Liu; R Pataky; A Potapov Journal: Curr Oncol Date: 2015-10 Impact factor: 3.677
Authors: Joseph Lipscomb; K Robin Yabroff; Mark C Hornbrook; Anna Gigli; Silvia Francisci; Murray Krahn; Gemma Gatta; Annalisa Trama; Debra P Ritzwoller; Isabelle Durand-Zaleski; Ramzi Salloum; Neetu Chawla; Catia Angiolini; Emanuele Crocetti; Francesco Giusti; Stefano Guzzinati; Maura Mezzetti; Guido Miccinesi; Angela Mariotto Journal: J Natl Cancer Inst Monogr Date: 2013
Authors: Nikki M Carroll; Thomas Delate; Alex Menter; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Debra P Ritzwoller Journal: J Oncol Pract Date: 2015-06-09 Impact factor: 3.840
Authors: Wendy G Anderson; Lynn A Flint; Jay R Horton; Kimberly Johnson; Michelle Mourad; Bradley A Sharpe Journal: J Hosp Med Date: 2013-11-08 Impact factor: 2.960